{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T05:48:47Z","timestamp":1782193727948,"version":"3.54.5"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s10157-026-02863-4","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T06:21:52Z","timestamp":1775542912000},"page":"987-997","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Epidemiological analysis of kidney involvement in systemic lupus erythematosus using the national database of designated intractable diseases of Japan: a cross-sectional study of renewal applicants"],"prefix":"10.1007","volume":"30","author":[{"given":"Hidekazu","family":"Ikeuchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoichi","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Isaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiei","family":"Narita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9490-8364","authenticated-orcid":false,"given":"Keiju","family":"Hiromura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"key":"2863_CR1","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1002\/acr.20683","volume":"64","author":"RW Jakes","year":"2012","unstructured":"Jakes RW, Bae SC, Louthrenoo W, et al. Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: prevalence, incidence, clinical features, and mortality. Arthritis Care Res. 2012;64:159\u201368.","journal-title":"Arthritis Care Res"},{"key":"2863_CR2","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/1529-0131(199901)42:1<46::AID-ANR6>3.0.CO;2-2","volume":"42","author":"KM Uramoto","year":"1999","unstructured":"Uramoto KM, Michet CJ Jr., Thumboo J, et al. Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992. Arthritis Rheum. 1999;42:46\u201350.","journal-title":"Arthritis Rheum"},{"key":"2863_CR3","first-page":"537","volume":"63","author":"VE Pollak","year":"1964","unstructured":"Pollak VE, Pirani CL, Schwartz FD. The natural history of the renal manifestations of systemic lupus erythematosus. J Lab Clin Med. 1964;63:537\u201350.","journal-title":"J Lab Clin Med"},{"key":"2863_CR4","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/0002-9343(87)90645-0","volume":"83","author":"GB Appel","year":"1987","unstructured":"Appel GB, Cohen DJ, Pirani CL, et al. Long-term follow-up of patients with lupus nephritis. a study based on the classification of the world health organization. Am J Med. 1987;83:877\u201385.","journal-title":"Am J Med"},{"key":"2863_CR5","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1002\/art.39594","volume":"68","author":"MG Tektonidou","year":"2016","unstructured":"Tektonidou MG, Dasgupta A, Ward MM. Risk of end-stage renal disease in patients with lupus nephritis, 1971-2015: a systematic review and bayesian meta-analysis. Arthritis Rheumatol. 2016;68:1432\u201341.","journal-title":"Arthritis Rheumatol"},{"key":"2863_CR6","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1136\/annrheumdis-2017-212732","volume":"77","author":"G Moroni","year":"2018","unstructured":"Moroni G, Vercelloni PG, Quaglini S, et al. Changing patterns in clinical-histological presentation and renal outcome over the last five decades in a cohort of 499 patients with Lupus Nephritis. Ann Rheum Dis. 2018;77:1318\u201325.","journal-title":"Ann Rheum Dis"},{"key":"2863_CR7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s41100-018-0183-6","volume":"4","author":"I Masakane","year":"2018","unstructured":"Masakane I, Taniguchi M, Nakai S, et al. Annual Dialysis Data Report 2016, JSDT renal data registry. Ren Replace Ther. 2018;4:45","journal-title":"Ren Replace Ther"},{"key":"2863_CR8","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ard.2025.09.007","volume":"85","author":"A Fanouriakis","year":"2026","unstructured":"Fanouriakis A, Kostopoulou M, Anders HJ, et al. EULAR recommendations for the management of systemic lupus erythematosus with kidney involvement: 2025 update. Ann Rheum Dis. 2026;85:75\u201390.","journal-title":"Ann Rheum Dis"},{"key":"2863_CR9","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1111\/nep.12863","volume":"22","author":"K Hiromura","year":"2017","unstructured":"Hiromura K, Ikeuchi H, Kayakabe K, et al. Clinical and histological features of lupus nephritis in Japan: a cross-sectional analysis of the Japan renal biopsy registry (J-RBR). Nephrology. 2017;22:885\u201391.","journal-title":"Nephrology"},{"key":"2863_CR10","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1007\/s10157-022-02232-x","volume":"26","author":"H Ikeuchi","year":"2022","unstructured":"Ikeuchi H, Sugiyama H, Sato H, et al. A nationwide analysis of renal and patient outcomes for adults with lupus nephritis in Japan. Clin Exp Nephrol. 2022;26:898\u2013908.","journal-title":"Clin Exp Nephrol"},{"key":"2863_CR11","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982\u201392.","journal-title":"Am J Kidney Dis"},{"key":"2863_CR12","doi-asserted-by":"publisher","first-page":"e000538","DOI":"10.1136\/lupus-2021-000538","volume":"8","author":"RF van Vollenhoven","year":"2021","unstructured":"van Vollenhoven RF, Bertsias G, Doria A, et al. 2021 DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Sci Med. 2021;8:e000538.","journal-title":"Lupus Sci Med"},{"key":"2863_CR13","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1136\/annrheumdis-2015-207726","volume":"75","author":"K Franklyn","year":"2016","unstructured":"Franklyn K, Lau CS, Navarra SV, et al. Definition and initial validation of a lupus low disease activity state (LLDAS). Ann Rheum Dis. 2016;75:1615\u201321.","journal-title":"Ann Rheum Dis"},{"key":"2863_CR14","doi-asserted-by":"publisher","first-page":"875","DOI":"10.3899\/jrheum.130704","volume":"41","author":"MB Urowitz","year":"2014","unstructured":"Urowitz MB, Gladman DD, Ibanez D, et al. American college of rheumatology criteria at inception, and accrual over 5 years in the SLICC inception cohort. J Rheumatol. 2014;41:875\u201380.","journal-title":"J Rheumatol"},{"key":"2863_CR15","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1002\/art.1780251101","volume":"25","author":"EM Tan","year":"1982","unstructured":"Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271\u20137.","journal-title":"Arthritis Rheum"},{"key":"2863_CR16","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1002\/art.1780400928","volume":"40","author":"MC Hochberg","year":"1997","unstructured":"Hochberg MC. Updating the american college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.","journal-title":"Arthritis Rheum"},{"key":"2863_CR17","first-page":"1955","volume":"30","author":"DD Gladman","year":"2003","unstructured":"Gladman DD, Urowitz MB, Rahman P, et al. Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol. 2003;30:1955\u20139.","journal-title":"J Rheumatol"},{"key":"2863_CR18","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1136\/ard.60.12.1145","volume":"60","author":"K Oinuma","year":"2001","unstructured":"Oinuma K, Harada Y, Nawata Y, et al. Osteonecrosis in patients with systemic lupus erythematosus develops very early after starting high dose corticosteroid treatment. Ann Rheum Dis. 2001;60:1145\u20138.","journal-title":"Ann Rheum Dis"},{"key":"2863_CR19","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1002\/acr.25528","volume":"77","author":"LR Sammaritano","year":"2025","unstructured":"Sammaritano LR, Askanase A, Bermas BL, et al. 2024 American college of rheumatology (ACR) guideline for the screening, treatment, and management of lupus nephritis. Arthritis Care Res. 2025;77:1045\u201365.","journal-title":"Arthritis Care Res"},{"key":"2863_CR20","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/acr.21664","volume":"64","author":"BH Hahn","year":"2012","unstructured":"Hahn BH, McMahon MA, Wilkinson A, et al. American college of rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res. 2012;64:797\u2013808.","journal-title":"Arthritis Care Res"},{"key":"2863_CR21","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1136\/annrheumdis-2012-201940","volume":"71","author":"GK Bertsias","year":"2012","unstructured":"Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European league against rheumatism and European renal association-European dialysis and transplant association (EULAR\/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71:1771\u201382.","journal-title":"Ann Rheum Dis"},{"key":"2863_CR22","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/kisup.2012.25","volume":"2","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group","year":"2012","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical practice guideline for glomerulonephritis. chapter 12: lupus nephritis. Kidney Int Suppl. 2012;2:221-32.","journal-title":"Kidney Int Suppl"},{"key":"2863_CR23","doi-asserted-by":"publisher","first-page":"618","DOI":"10.3109\/14397595.2013.844397","volume":"24","author":"H Ikeuchi","year":"2014","unstructured":"Ikeuchi H, Hiromura K, Takahashi T, et al. Efficacy and safety of multi-target therapy using a combination of tacrolimus, mycophenolate mofetil and a steroid in patients with active lupus nephritis. Mod Rheumatol. 2014;24:618\u201325.","journal-title":"Mod Rheumatol"},{"key":"2863_CR24","doi-asserted-by":"publisher","DOI":"10.1177\/0961203318758505","author":"CB Choi","year":"2018","unstructured":"Choi CB, Won S, Bae SC. Outcomes of multitarget therapy using mycophenolate mofetil and tacrolimus for refractory or relapsing lupus nephritis. Lupus. 2018;7(6):1007\u201311.","journal-title":"Lupus"},{"key":"2863_CR25","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1136\/annrheumdis-2017-211631","volume":"77","author":"F Zhang","year":"2018","unstructured":"Zhang F, Bae SC, Bass D, et al. A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. Ann Rheum Dis. 2018;77:355\u201363.","journal-title":"Ann Rheum Dis"},{"key":"2863_CR26","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1912196","volume":"382","author":"EF Morand","year":"2020","unstructured":"Morand EF, Furie R, Tanaka Y, et al. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020;382:211\u201321.","journal-title":"N Engl J Med"},{"key":"2863_CR27","doi-asserted-by":"publisher","first-page":"759","DOI":"10.3109\/s10165-012-0733-7","volume":"23","author":"A Ohta","year":"2013","unstructured":"Ohta A, Nagai M, Nishina M, Tomimitsu H, Kohsaka H. Age at onset and gender distribution of systemic lupus erythematosus, polymyositis\/dermatomyositis, and systemic sclerosis in Japan. Mod Rheumatol. 2013;23:759\u201364.","journal-title":"Mod Rheumatol"},{"key":"2863_CR28","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2020.11.003","volume":"99","author":"Kidney Disease: Improving Global Outcomes Blood Pressure Work G","year":"2021","unstructured":"Kidney Disease: Improving Global Outcomes Blood Pressure Work G. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 2021;99:S1\u201387.","journal-title":"Kidney Int"},{"key":"2863_CR29","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1093\/mr\/roab088","volume":"32","author":"K Nagasaka","year":"2022","unstructured":"Nagasaka K, Kaname S, Amano K, et al. Nation-wide survey of the treatment trend of microscopic polyangiitis and granulomatosis with polyangiitis in Japan using the Japanese ministry of health. Labour Welf Database Mod Rheumatol. 2022;32:915\u201322.","journal-title":"Labour Welf Database Mod Rheumatol"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-026-02863-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-026-02863-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-026-02863-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T05:40:18Z","timestamp":1782193218000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-026-02863-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["2863"],"URL":"https:\/\/doi.org\/10.1007\/s10157-026-02863-4","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,7]]},"assertion":[{"value":"28 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"S. Maruyama has received grants\/research support from Rohto Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma, Zenyaku Kogyo, Nipro Corporation, and honoraria from AstraZeneca, Alexion Pharma, Mitsubishi Tanabe Pharma, Ono Pharmaceutical, Kyowa Kirin, Torii Pharmaceutical, Nippon Boehringer Ingelheim, Otsuka Pharmaceutical, and scholarship donations from Otsuka Pharmaceutical and Torii Pharmaceutical. I. Narita has received speaker\u2019s fees from Otsuka Pharmaceutical, Sanofi, Bayer Yakuhin, Kyowa Kirin, and research grants from Bayer Yakuhin, Chugai Pharmaceutical, Kyowa Kirin, Terumo, Kaneka, Otsuka Pharmaceutical, Daiichi Sankyo, Astellas Pharma, Sumitomo Pharma, Ono Pharmaceutical, and Amicus Therapeutics. K. Hiromura has received consultancy fees from Otsuka Pharmaceutical and GlaxoSmithKline, grants\/research support from Chugai Pharmaceutical, and honoraria from Astellas Pharma, AstraZeneca, Asahi Kasei Pharma, GlaxoSmithKline, Kissei Pharmaceutical, and Otsuka Pharmaceutical.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This retrospective cross-sectional study followed the guidelines of the Declaration of Helsinki. It was approved by the Ethics Committee of the Japanese Society of Nephrology (approval number 70) and the Ethics Committee of Gunma University Graduate School of Medicine (approval number HS2019-280).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from patients for the registration of data derived from their Medical Certificates of the National Database of Designated Intractable Diseases in Japan and for the use of these data for research and policymaking.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}